Thursday, July 14, 2022
12:00PM – 1:00PM ET
Please note this TeleECHO program is 12:00PM Eastern, 11:00AM Central, 10:00AM Mountain and 9:00AM Pacific.
PROGRAM OVERVIEW
This live virtual TeleECHO program will explore key clinical practice insights for management of patients with BRAF-mutated metastatic melanoma. Over the course of this activity there will be discussion of the clinical profiles of frontline combination immuno- and targeted treatment options in BRAF-mutated metastatic melanoma as well as emerging data from clinical trials and real-world studies examining sequencing of these therapies. Interactive case studies will illustrate strategies for treatment selection, mitigation of adverse events, and management considerations for patients with BRAF-mutated metastatic melanoma.
PROGRAM CHAIR
Jeffrey S. Weber, MD, PhD
Deputy Director, Laura and Isaac Perlmutter Cancer Center
Co-Director, Melanoma Research Program
Professor of Medicine, NYU Grossman School of Medicine
New York, NY
Presenting Faculty:
Isabella C. Glitza Oliva, MD, PhD
Associate Professor
Melanoma Medical Oncology
MD Anderson Cancer Center
Houston, TX
Learning Objectives
Upon the completion of this program, attendees should be able to:
- Assess the clinical profiles of frontline combination immuno- and targeted treatment options used for the management of BRAF-mutated metastatic melanoma
- Evaluate data from clinical trials and real-world studies examining the effects of sequencing frontline combination immuno- and targeted treatment options for the management of BRAF-mutant metastatic melanoma
- Identify the AEs associated with frontline combination immuno- and targeted treatment options for BRAF-mutated metastatic melanoma in order to mitigate them should they arise
Target Audience
This activity is intended for community-based medical oncologists, and other allied healthcare practitioners involved in the management and treatment of patients with metastatic melanoma.
ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this live virtual activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the live virtual activity.
NURSING CREDIT INFORMATION
Purpose: This program would be beneficial for nurses involved in the care of patients with melanoma.
CNE Credits: 1.0 ANCC Contact Hour.
CNE ACCREDITATION STATEMENT
Ultimate Medical Academy/Complete Conference Management (CCM) is accredited as a provider of nursing continuing professional education development by the American Nurses Credentialing Center’s Commission on Accreditation.
Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During this lecture, the faculty may mention the use of medications for both FDA-approved and nonapproved indications.
Med Learning Group makes every effort to develop CME activities that are science-based.
This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at [email protected]
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/
